Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 2/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | CDK1 | P06493 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | WEE1 | P30291 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | IGF1R | P08069 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114726 | 0.97 | LMNA (0.48) | LMNATNK2PLK1MEN1KMT2A | |
| SCHEMBL2114807 | 0.92 | LMNA (0.50) | LMNATNK2MEN1KMT2ACSF1R | |
| SCHEMBL2113295 | 0.91 | IGF1R (0.43) | TNK2PLK1IGF1R | |
| SCHEMBL2113595 | 0.88 | IGF1R (0.44) | TNK2PLK1FGFR1SLC6A4KDR | |
| SCHEMBL2114805 | 0.88 | TNK2 (0.46) | TNK2FGFR1SLC6A4CDK1KDR | |
| SCHEMBL2113867 | 0.84 | TNK2 (0.46) | TNK2PLK1FGFR1SLC6A4CDK1 | |
| SCHEMBL2116066 | 0.83 | HTT (0.42) | LMNATNK2PLK1KMT2AMAPT | |
| SCHEMBL2116118 | 0.83 | HTT (0.46) | LMNATNK2KMT2AMAPT | |
| SCHEMBL2115650 | 0.83 | IGF1R (0.46) | TNK2CDK1KDRIGF1R | |
| SCHEMBL2112982 | 0.83 | JAK2 (0.35) | PLK1KMT2AMAPTKDRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158641-B2 | 2-anilino-4-aminoalkyleneaminopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-17 | — | — | US | disclosed |
| US-20090181995-A1 | 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-16 | — | — | US | disclosed |
| EP-2032543-A1 | 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES | Boehringer Ingelheim International GmbH (DE) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007146977-A1 | 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-21 | — | — | WO | disclosed |
| US-20070293525-A1 | 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293525-A1 | 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES | PRKCA, PRKCH, PRKCG | LMNA 975/4885TNK2 195/4885PLK1 644/4885 |
| US-20090181995-A1 | 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES | PRKCA, PRKCH, PRKCG | LMNA 975/4885TNK2 195/4885PLK1 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.